Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Pilar Giraldo, MD PhD, Andres Lopez, MD PhD, Eduardo Rios, MD, Felix Carbonell, MD PhD, Javier Lopez, Angel Ramírez, MD, Alicia Rodriguez, MD, Marta Gomez, MD, Ricardo Garcia, MD, Patricia Baltasar, MD, Maria Duran, MD, Raul Perez, MD, Maria Garcia, MD, José Antonio Márquez, Javier De la Serna, MD PhD

Blood (2014) 124 (21): 5666.

https://doi.org/10.1182/blood.V124.21.5666.5666

Published: 2014

Journal Articles

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Pau Abrisqueta, MD, Neus Villamor, MD, PhD, María José Terol, MD, PhD, Eva González-Barca, MD, PhD, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose Antonio García-Marco, MD, PhD, Yolanda González, MD, Felix Carbonell, MD, PhD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, MD, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3930.

https://doi.org/10.1182/blood.V120.21.3930.3930

Published: 2012

Journal Articles

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Blood (2012) 120 (21): 4956.

https://doi.org/10.1182/blood.V120.21.4956.4956

Published: 2012

Journal Articles

Response Predictive Factors to Anagrelide in Essential Thrombocythemia Diagnosed Patients.

Carlos Besses, MD, PhD, Manuel Giralt, MD, PhD, Luis Hernandez-Nieto, MD, PhD, Carmen Burgaleta, MD, PhD, Victor Navas, MD, PhD, Gema Ramirez, MD, PhD, Vicente Vicente, MD, PhD, Felix Carbonell, MD, PhD

Blood (2007) 110 (11): 4649.

https://doi.org/10.1182/blood.V110.11.4649.4649

Published: 2007

Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD

Blood (2007) 110 (11): 626.

https://doi.org/10.1182/blood.V110.11.626.626

Published: 2007

NARROW

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Response Predictive Factors to Anagrelide in Essential Thrombocythemia Diagnosed Patients.

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Response Predictive Factors to Anagrelide in Essential Thrombocythemia Diagnosed Patients.

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only